Abstract Body

ART fails to restore the depletion of Th17-polarized CCR6+CD4+ T-cells in PLWH. Novel Th17-targeted HIV remission/cure strategies are needed to restore Th17-mediated mucosal immunity. Autoimmunity studies demonstrated the existence of pathogenic and non-pathogenic Th17 cells and identified the aryl hydrocarbon receptor (AhR) as a marker of non-pathogenic Th17 cells. AhR is a ligand-dependent transcription factor that regulates the expression of several genes (IL-22, IL-10, integrin B7) and is involved in proteasomal degradation via its E3 ubiquitin ligase activity. We hypothesized that AhR negatively regulates HIV replication in non-pathogenic Th17 cells.

 

PBMC of ART-treated PLWH (n=8; median CD4 counts: 598, plasma viral load < 40 HIV-RNA copies/ml) and uninfected controls (n=5) were used in this study. Total/CCR6+/CCR6- memory CD4+ T-cells were isolated by magnetic/flow cytometry sorting. Cells of uninfected donors were stimulated via CD3/CD28, exposed to HIV, and cultured 9 days. Viral outgrowth assay (VOA) was performed with cells of ART-treated PLWH. AhR silencing was performed using CRISPR/cas9, with efficacy evaluated by T7 endonuclease assay and Western blotting. AhR agonist (FICZ) and antagonist (CH223191) were used. Cell viability/proliferation, HIV replication, cytokines, and gene expression were quantified by ELISA, flow cytometry and/or real-time PCR.

AhR mRNA/protein expression was induced by T-cell receptor triggering. CRISPR/cas9-mediated AhR silencing significantly inhibited IL-22, IL-17A, IL-10 and integrin beta7 expression (p<0.01) and increased viral replication upon infection in vitro (n=3; p=0.0084). Similarly, CH223191 significantly down regulated IL-22, IL-17A, IL-10, production (p<0.0001); increased wild type HIV replication (p=0.0016), as well as HIV-DNA integration/transcription upon single-round infection with HIV-VSVG pseudotyped viruses (n=5; p=0.001); and increased >2-fold HIV reactivation in VOA (n=7). At the opposite, FICZ significantly increased IL-22 and IL-10 production and inhibited viral replication in vitro and reactivation in VOA.

Our results identify the AhR as a novel negative regulator of HIV replication in Th17/Th22-polarized cells thus raising the interest in testing natural/synthetic AhR agonists/antagonists for HIV remission/cure strategies.